UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
| (State
of Incorporation) |
(Commission
File Number) |
(IRS
employer identification no.) |
(Address of principal executive offices, including zip code)
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On November 8, 2023, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the three months ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| No. | Description | |
| 99.1 | Press Release, dated November 8, 2023 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 8, 2023
| INTELLIGENT BIO SOLUTIONS INC. | ||
| By: | /s/ Spiro Sakiris | |
| Name: | Spiro Sakiris | |
| Title: | Chief Financial Officer | |
Exhibit 99.1
Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights
- First fiscal quarter revenue and government support income increased 191% year-over-year and 88% sequentially due to strong organic growth and execution of expansion plans –
- Increased market share organically in existing markets and entered South American market –
- Advanced plans for expansion into the U.S. market –
- Completed critical development milestone in plans to add new assays for ketamine and tramadol to the Intelligent Fingerprinting Drug Screening System -
NEW YORK, November 08, 2023 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal first quarter ended September 30, 2023, and provided a business update.
“We achieved strong revenue growth over the first quarter of fiscal 2024, maintaining the momentum we have built over the past several quarters,” commented Harry Simeonidis, President and Chief Executive Officer of Intelligent Bio Solutions Inc. “This growth is largely attributable to the increasing acceptance of our proprietary Intelligent Fingerprinting Drug Screening System by customers, which has translated to consistent sales and increased revenue. The sustained rising demand for our innovative screening product across a diverse number of industries demonstrates its versatility and its value as a faster, more efficient, and less-invasive drug screening solution for workplaces.”
“We expanded our market presence in South America while advancing our reach in existing markets. We are now focused on executing our plan to enter the U.S. market after receiving FDA guidance on a regulatory pathway for our Intelligent Fingerprinting Drug Screening Cartridge earlier this year.” Mr. Simeonidis added.
First Quarter & Recent Highlights:
| ● | Expanded into the New Zealand market, representing a significant milestone in the Company’s growth strategy for its Intelligent Fingerprinting Drug Screening System. | |
| ● | Enhanced customer portfolio with specialist container logistics firm VKVP Haulage adopting the Company’s Intelligent Fingerprinting Drug Screening System. Additionally, existing customer Auctus Management Group completed 25,000 tests using the Company’s Intelligent Fingerprinting Drug Screening System. | |
| ● | Obtained recertification for ISO 13485: 2016, which is the international standard for medical systems quality management system certification. | |
| ● | Completed critical development milestone in plans to add new assays for ketamine and tramadol to the Intelligent Fingerprinting Drug Screening System. The new assays passed the Company’s initial design phase and are ready for scale-up and transfer to manufacture ahead of potential clinical trials. |
| ● | Secured eight new customers across Australia for its Intelligent Fingerprinting Drug Screening System product. The customers come from a variety of industries including mining, aviation, construction, manufacturing, and agriculture, and are using it to promote alternative screening practices. | |
| ● | Signed a South American distribution deal with TSCOM SPA for the Company’s Intelligent Fingerprinting Drug Screening System and secured its first order under this agreement. |
First Fiscal Quarter Ended September 30, 2023, Financial Results
All amounts are expressed in U.S. dollars unless indicated otherwise. All authorized, issued, and outstanding stock and per share amounts reflect the 1-for-20 reverse stock split effected by the Company on February 9, 2023, unless indicated otherwise.
The Company’s combined revenue and government support income increased by 191% to $0.91 million for the first fiscal quarter ended September 30, 2023, including revenue from sales of goods of $0.8 million, compared to $0 in the first fiscal quarter ended September 30, 2022. The increase in revenue is due to the acquisition of Intelligent Fingerprinting Ltd (“IFP”) in October 2022 and the launch of its Intelligent Fingerprinting Drug Screening System in the Asia-Pacific region via Intelligent Bio Solutions (APAC) Pty Ltd.
Net loss attributable to INBS for the first fiscal quarter ended September 30, 2023 was $2.4 million, compared to a net loss of $1.2 million for the first fiscal quarter of the prior fiscal year. This increase is primarily driven by the combined results of operations after the acquisition of IFP offset by a recognition of fair value gain on revaluation of holdback Series C Preferred Stock during the current quarter of $131,250.
The Company ended the quarter with cash and cash equivalents of approximately $0.2 million. On October 4, 2023, subsequent to the quarter ended September 30, 2023, the Company raised approximately $4.378 million prior to deducting underwriting discounts and commissions and offering expenses via a registered underwritten public offering of the Company’s securities. Net proceeds to the Company, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $3.35 million.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (the “Company”) (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. This hygienic, and cost-effective system is designed to screen for recent use of drugs commonly found in the workplace, including opioids, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its screening and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘projects,’’ ‘‘intends,’’ ‘‘potential,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘approximately’’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
Media Contact:
Cheryl Billson
Comma Communications
cheryl.billson@commacomms.com
Investor Contact:
Valter Pinto
KCSA Strategic Communications
INBS@kcsa.com
Intelligent Bio Solutions Inc.
Condensed Consolidated Balance Sheets
(Amounts in US$)
| September 30, 2023 (Unaudited) | June 30, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 186,401 | $ | 1,537,244 | ||||
| Accounts receivable, net | 567,510 | 293,861 | ||||||
| Inventories, net | 965,091 | 979,907 | ||||||
| Research and development tax incentive receivable | 559,588 | 498,758 | ||||||
| Other current assets | 413,305 | 552,791 | ||||||
| Total current assets | 2,691,895 | 3,862,561 | ||||||
| Property and equipment, net | 664,922 | 690,175 | ||||||
| Operating lease right-of-use assets | 471,532 | 546,475 | ||||||
| Intangible assets, net | 4,872,141 | 5,255,401 | ||||||
| TOTAL ASSETS | $ | 8,700,490 | $ | 10,354,612 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 3,628,797 | $ | 2,610,028 | ||||
| Current portion of operating lease liabilities | 227,414 | 223,447 | ||||||
| Current portion of deferred grant income | 2,240,929 | 2,338,057 | ||||||
| Current employee benefit liabilities | 406,964 | 358,942 | ||||||
| Current portion of notes payable | 341,834 | 353,211 | ||||||
| Total current liabilities | 6,845,938 | 5,883,685 | ||||||
| Employee benefit liabilities, less current portion | 27,732 | 24,902 | ||||||
| Operating lease liabilities, less current portion | 284,028 | 356,165 | ||||||
| Notes payable, less current portion | 306,234 | 402,862 | ||||||
| Total liabilities | 7,463,932 | 6,667,614 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders’ equity: | ||||||||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 2,330,399 shares issued and outstanding at September 30, 2023 and June 30, 2023, respectively | 23,304 | 23,304 | ||||||
| Treasury stock, at cost, 1,386 shares as of September 30, 2023 and June 30, 2023, respectively | (14 | ) | (14 | ) | ||||
| Additional paid-in capital | 46,158,763 | 46,158,763 | ||||||
| Accumulated deficit | (44,232,777 | ) | (41,807,573 | ) | ||||
| Accumulated other comprehensive loss | (593,512 | ) | (575,496 | ) | ||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 1,355,764 | 3,798,984 | ||||||
| Non-controlling interest | (119,206 | ) | (111,986 | ) | ||||
| Total shareholders’ equity | 1,236,558 | 3,686,998 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 8,700,490 | $ | 10,354,612 | ||||
Intelligent Bio Solutions Inc.
Condensed Consolidated Statements of Operations and Other Comprehensive Loss*
(Unaudited)
(Amounts in US$)
| Three Months Ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Revenue | $ | 796,094 | $ | - | ||||
| Cost of revenue (exclusive of amortization shown separately below) | (563,763 | ) | - | |||||
| Gross profit | 232,331 | - | ||||||
| Other income: | ||||||||
| Government support income | 109,871 | 311,320 | ||||||
| Operating expenses: | ||||||||
| Selling, general and administrative expenses | (2,457,060 | ) | (1,450,418 | ) | ||||
| Development and regulatory approval expenses | (103,947 | ) | (79,274 | ) | ||||
| Depreciation and amortization | (307,560 | ) | - | |||||
| Total operating expenses | (2,868,567 | ) | (1,529,692 | ) | ||||
| Loss from operations | (2,526,365 | ) | (1,218,372 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | (37,448 | ) | (1,065 | ) | ||||
| Realized foreign exchange loss | - | (2,247 | ) | |||||
| Fair value gain on revaluation of financial instrument | 131,250 | - | ||||||
| Interest income | 139 | 7,606 | ||||||
| Total other income | 93,941 | 4,294 | ||||||
| Net loss | (2,432,424 | ) | (1,214,078 | ) | ||||
| Net loss attributable to non-controlling interest | (7,220 | ) | (5,785 | ) | ||||
| Net loss attributable to Intelligent Bio Solutions Inc. | $ | (2,425,204 | ) | $ | (1,208,293 | ) | ||
| Other comprehensive loss, net of tax: | ||||||||
| Foreign currency translation loss | $ | (18,016 | ) | $ | (135,559 | ) | ||
| Total other comprehensive loss | (18,016 | ) | (135,559 | ) | ||||
| Comprehensive loss | (2,450,440 | ) | (1,349,637 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | (7,220 | ) | (5,785 | ) | ||||
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | $ | (2,443,220 | ) | $ | (1,343,852 | ) | ||
| Net loss per share, basic and diluted* | $ | (1.04 | ) | $ | (1.62 | ) | ||
| Weighted average shares outstanding, basic and diluted* | 2,330,399 | 744,495 | ||||||
| * | Common Stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated. |